Canadian Association of Psoriasis Patients – Biosimilar Position Statement
Visit Canadian Psoriasis Biosimilar Position Statement to read their recommendations. These recommendations include: If a drug plan is considering non-medical switching, If a drug plan is considering tiering All drug plans implementing biosimilar policies should conduct robust post-implementation surveillance.
L’amour et la maladie sont deux notions compatibles
Version française 1er article : L’amour et la maladie sont deux notions compatibles. Nous avons le droit nous aussi à l’amour !!! Depuis quelques années, je lis de nombreux posts sur le désespoir de trouver quelqu’un lorsqu’on est atteint de maladie de Verneuil, ou même d’une autre pathologie. Je reçois des messages de personnes qui
Understanding the mRNA Vaccine
Let’s take a deeper look into what mRNA vaccines are in relation to Covid-19. Traditionally vaccines used to prevent the flu, or polio, contained either a purified signature protein of the virus, or a weakened strain of the virus. These are known as Killed Vaccines or Live Vaccines. Messenger RNA vaccines, also known as mRNA
An HS Hero’s Journey
We are sitting in his car. There is one thought running through my mind, and one thought only: Please don’t leave a stain on his seat. Please, please, please don’t leave a stain on his seat. The thought taunts me, circling my mind incessantly, until the moment of truth arrives and I find myself saying
Position Statement on Biosimilars
HS Heroes Biosimilars Position Statement: October 2020 Biosimilars are a safe and effective treatment for people living with Auto-Immune/Auto-Inflammatory Disease. The decision to switch a patient from an Innovator Biologic Drug to its Biosimilar should be based on patient/doctor choice. Non-Medical switching from an Innovator Biologic to its biosimilar, while safe, is not always in
Global Hidradenitis Suppurativa COVID-19 Registry
This is an international pediatric and adult database to monitor and report outcomes of COVID-19 occurring in hidradenitis suppurativa (HS) patients. We will use these data to better understand risk of infection and clinical course, track outcomes, and inform HS management in the setting of COVID-19. Cases can be reported by healthcare professionals caring for HS
Scarred for Life
In January 2020 The Canadian Skin Patient Alliance team collaborated with Health Care professionals, and a patient representative to conduct a survey to identify if progress had been made in improving the diagnostic process, and the ongoing care and treatment for HS. Click on the links to see the results of those surveys
HS Clinical Guidelines
In 2019 the United States and Canadian Hidradenitis Suppurativa foundations published the North American clinical management guidelines for Hidradenitis Suppurativa. Part I Addresses Diagnosis, evaluation, and the use of complementary and procedural management. https://www.jaad.org/article/S0190-9622(19)30367-6/fulltext Part II addresses Topical, intralesional, and systemic medical management. https://www.jaad.org/article/S0190-9622(19)30368-8/fulltext
Voices of HS Unite
As part of #HSAwarenessWeek, check out the Voices of HS Unite campaign, a photo compilation made possible by Abbvie Canada. Events may be cancelled, but hope and community support are not. Thanks to everyone who shared a message! #HSHope #HonestWithHS #VoicesofHSUnite https://www.youtube.com/watch?v=cB6sIZn9tM4&t